VVVV vVARDIS Holding AG 424B4 final IPO prospectus section summaries
An AI model summarized each section of the prospectus on its own; the summary was written from these. They are longer and less edited than the summary, and the filing on SEC is the authority.
Cover page
Offering
vVARDIS Holding AG is offering 9,722,223 Class A ordinary shares at $18.00 per share, for approximately $175.0 million in gross proceeds. Underwriting discounts and commissions total $12.25 million ($1.26 per share), leaving approximately $162.75 million ($16.74 per share) before offering expenses. The company has also agreed to reimburse certain underwriter expenses. Underwriters have a 30-day option to purchase up to 1,458,333 additional Class A shares to cover over-allotments.
The prospectus is dated November 12, 2026, and the shares were expected to be delivered on or about November 16, 2026. The NYSE approved the listing under ticker VVVV.
Share structure and voting control
Before the offering, the company will reorganize its share capital into Class A ordinary shares and Class B voting rights shares. Each class carries one vote per share, but Class B shares have one-tenth the par value of Class A shares (CHF 0.0006 versus CHF 0.006), giving Class B holders ten times the voting power per unit of par value. Class B shares are subject to transfer restrictions and mandatory conversion in specified circumstances, including individual founder sunset events.
Founders Haley and Goly Abivardi will beneficially own all Class B shares. After the offering, assuming no exercise of the over-allotment option, they will control 86.9% of total voting power, concentrating influence over board elections, charter changes, and significant corporate transactions.
Company status
The company identifies as an emerging growth company, foreign private issuer, and NYSE controlled company, and may use reduced disclosure and corporate-governance requirements. The prospectus directs investors to the risk factors beginning on page 21.
About this prospectus
About this prospectus
Reporting basis and comparability
The company’s fiscal year ends December 31. Its consolidated financial statements are presented in U.S. dollars and prepared under U.S. GAAP; subsidiaries maintain records in local currencies, including CHF, GBP and EUR, and their results are translated into dollars. Deloitte AG audited the financial statements prepared under GAAP.
The prospectus also presents unaudited, non-GAAP illustrative financial information for the six months ended June 30, 2026. It was calculated by subtracting unaudited H1 2025 results from FY 2025 results and adding H1 2026 interim results. Historical share and per-share information reflects the pre-offering capital structure and does not reflect the dual-class reclassification that takes effect immediately before the offering is completed. The stated exchange rate is $1.0000 = CHF 0.82085, based on spot rates on November 5, 2026.
The company uses Adjusted EBITDA as a supplemental non-GAAP measure; its definition and reconciliation to the closest GAAP measure are provided elsewhere in the prospectus.
Market estimates and opportunity
The company’s TAM, SAM and industry estimates draw on management analysis, third-party sources and internal research. Sources generally have not been independently verified, and internal estimates rely on assumptions; actual market opportunity may be smaller than estimated.
The company estimates the U.S. population at approximately 342 million. About 63%–65% visit a dentist at least annually, while approximately 35%–37% do not. It estimates that 75%–85% of the U.S. population has at least one early-stage, enamel-only cavity. This is distinct from the cited 2.5 billion people globally affected by tooth decay, a figure concerning advanced cavitated cavities under WHO surveillance methodology.
Early-stage cavities are estimated to average 4.6 per affected patient. After an approximately 9% reduction—because one application can treat certain neighboring cavities on both surfaces of the same gap—the estimate is 4.2 treatable cavities per affected patient. The estimate relies mainly on clinical and academic studies; its primary prevalence study was European, supplemented by limited U.S. study and partner data.
- TAM applies estimated prevalence to the full U.S. population, including people who do not visit a dentist annually. It assumes non-visitors have at least the prevalence of dental visitors and that 100% of early-stage cavities are detected.
- SAM applies approximately 65% annual dental visitation and current unaided detection rates. It is estimated at at least 450 million treatable early-stage cavities—a cavity-count estimate, not a dollar market-size figure.
Dentists are estimated to detect 65%–69% of early-stage cavities without AI. This estimate combines lower detection of interproximal cavities, which account for about 75% of early-stage cavities, with higher detection on other surfaces. The company estimates AI could raise identification by 30%–40% relative to unaided assessment, based on cited studies and FDA 510(k) submissions. Those potential AI-driven gains are not included in current SAM. Management says broader AI use and improved treatment acceptance could expand the opportunity by more than 30%.
Pricing assumptions use current U.S. selling prices and generally assume one Curodont® application per early-stage cavity. Actual use may be lower per cavity, including when one application treats neighboring teeth, which could reduce the opportunity.
Principal assumptions and risks
The estimates assume no material change in provider behavior or the regulatory framework, including Curodont® Repair Fluoride Plus remaining an OTC drug product under the FDCA. Actual disease prevalence, dental visitation, detection rates, product utilization, pricing and treatment behavior may differ from the assumptions. Potential market expansion from AI is prospective and is not reflected in SAM.
Cautionary statement regarding forward looking s
Forward-Looking Statements and Principal Risks
VVVV’s forward-looking statements cover its Curodont® products and technology platform, including anticipated demand and market growth; customer and patient adoption; product innovation; and expansion of its networks of dental professionals, distributors, and strategic partners. Execution depends on competing effectively, expanding sales and marketing, increasing awareness of the products’ clinical and commercial benefits, and scaling operations.
The company identifies risks related to distributor and customer performance and payment obligations, collection of accounts receivable, and its ability to meet its own contractual obligations. It also depends on key suppliers, manufacturers, and service providers, and faces risks in manufacturing, fulfillment, and distribution. Other risks include protecting and enforcing intellectual property; obtaining regulatory approvals and maintaining compliance; changes in healthcare laws and reimbursement practices; international expansion and foreign-exchange exposure; and attracting and retaining qualified personnel.
Demand may be affected by the elective nature of dental care and consumer spending, as well as macroeconomic and geopolitical conditions, inflation, and public-health crises. VVVV also flags potential cybersecurity and information-technology disruptions and uncertainties associated with using artificial intelligence, machine learning, automation, and digital tools. Company-specific matters identified as uncertainties include the Co-Founders’ and Co-CEOs’ personal indebtedness and repayment plans, the multi-class share structure, and the intended use of offering proceeds.
VVVV’s expectations include achieving and sustaining profitability and positive cash flow, but these results are not assured. Actual results may differ materially and adversely from expectations because of risks, uncertainties, assumptions, and new or unforeseeable risks. Forward-looking statements reflect information available when made, may rely on incomplete information, and should not be treated as predictions. VVVV generally disclaims an obligation to update these statements after the prospectus date, except as required by law.
Prospectus summary
Business and products
vVARDIS develops Curodont®, a peptide-based, drill-free treatment intended to arrest or reverse early-stage cavities while preserving natural tooth structure. Its U.S. flagship, Curodont® Repair Fluoride Plus, generates the vast majority of revenue; Curodont® Repair is sold in other markets. The products target ICDAS 1–2 early lesions and may not be suitable for more advanced decay. Treatment is described as a chairside procedure taking five minutes or less, in one visit, without anesthesia or specialized equipment. The company cites more than 250 scientific publications and a 25-year evidence base.
The company positions Curodont between prevention and invasive restorative care. It says fluoride varnish does not treat established lesions, silver diamine fluoride can stain teeth, and fillings and more advanced procedures remove tooth structure. Since the U.S. launch in January 2024, its products had treated an estimated 3.5 million-plus teeth by June 30, 2026. The flagship products had reached more than 20,000 of approximately 110,000 U.S. general dental practices.
Financial performance
| Metric | FY 2025 | H1 2026 | H1 2025 |
|---|---|---|---|
| Net revenue | $30.2M | $28.6M (+214.2% YoY) | — |
| Gross profit | $22.4M | $24.7M | — |
| Gross margin | 74.2% | 86.4% | 51.4% |
| Net loss | — | $(27.8)M | — |
At June 30, 2026, accumulated deficit was $256.3M. The company attributes its gross-margin profile partly to an asset-light model.
Preliminary nine-month results are unaudited, unreviewed estimates subject to closing procedures, valuation judgments and revision; they are not necessarily indicative of FY 2026 or future results.
| Metric | 9M 2026 estimate | 9M 2025 |
|---|---|---|
| Net revenue | $47.7M–$49.2M | $22.287M |
| Gross profit | $41.1M–$42.3M | $15.378M |
| Gross margin | 86.0%–86.2% | 69.0% |
| Net loss | $(39.7)M–$(41.3)M | $(40.671)M |
| Interest expense | $13.8M–$14.1M | $7.136M |
| Adjusted EBITDA loss (non-GAAP) | $(9.2)M–$(9.4)M | $(17.127)M |
| Cash and cash equivalents | $19.4M at Sept. 30, 2026 | $17.5M at Dec. 31, 2025 |
Estimated revenue growth of $25.4M–$26.9M was primarily U.S.-driven, contributing $24.9M–$26.3M. Curodont Repair Fluoride Plus sales rose 112% to approximately 214,000 units. Gross-margin improvement reflected a 60% reduction in Curodont unit manufacturing costs after the third-generation manufacturing process launch and logistics costs declining to 1% of revenue from 2%; higher unit sales added $6.6M of costs. Increased operating and interest expense largely offset higher gross profit.
The Adjusted EBITDA reconciliation includes share-based compensation of $5.5M–$5.8M (9M 2025: $9.917M), restructuring and advisory costs of $2.2M–$2.3M, a $1.6M term-loan extinguishment loss, a $1.2M fair-value loan loss, a $1.6M loan-conversion gain, a $2.3M–$2.5M derivative-liability fair-value loss and foreign-exchange losses of $2.1M–$2.6M. Management reports losses since inception, expects continued losses, may require additional capital and warns indebtedness may increase.
Market, commercialization and development
vVARDIS estimates a U.S. total addressable market of about $29B, based on roughly 1 billion early-stage cavities, and a serviceable market of at least $13B for at least 450 million identified and clinically managed cavities. It estimates AI-enabled detection could expand the opportunity by more than 30%; at 100% detection, estimated SAM would be at least $20B. These are company estimates, including cavities among people who do not regularly visit a dentist.
Commercialization is initially focused on the U.S. and Europe. In the U.S., the hybrid model combines a specialized direct team with Henry Schein as exclusive distributor in the U.S. and U.K. As of September 30, 2026, the company had 68 key account managers, 9 internal sales representatives, 9 clinical education specialists and a 12-person marketing team. Awareness remains limited; efforts include dental-school curricula, key opinion leader advocacy, in-office and direct-to-patient marketing pilots, and participation in more than 50 U.S. and European dental programs.
Development plans include next-generation peptides, additional clinical applications and AI/ML capabilities, including potential products for later-stage cavities and hard- and soft-tissue conditions; the company is also evaluating applications outside dentistry.
Risks, ownership and reporting
Key risks include adoption of a new treatment category, clinician and patient awareness, accurate lesion detection, reliance on distributors (particularly Henry Schein), key customers including Heartland Dental, and third-party manufacturers and suppliers. The company also cites uncertainty in market estimates, competition and scientific change, regulatory and marketing-claims exposure, recalls, intellectual-property, AI, privacy and cybersecurity risks, potential goodwill and intangible-asset impairment, and inability to use tax attributes. In the U.S., Repair Fluoride Plus is regulated as an OTC drug based on its sodium fluoride content; the FDA has not determined its safety or efficacy.
A five-for-three forward share split was completed in September 2026, with historical share information retroactively adjusted. Before the offering, outstanding ordinary and preferred shares convert into 42,771,805 Class A ordinary shares; 14,388,879 Class A shares then convert into 143,888,790 Class B voting rights shares. After reorganization, stated capital is 28,327,460 Class A shares, excluding 55,466 treasury shares, and 143,888,790 Class B voting rights shares. Founders are expected to hold 86.9% of voting power after the offering, making vVARDIS a controlled company.
The company expects to qualify as a foreign private issuer and emerging growth company. It intends to use certain NYSE governance exemptions and reduced SEC reporting requirements, including no quarterly Form 10-Q or current Form 8-K reporting while eligible, and has elected the extended transition period for new accounting standards. These provisions may reduce investor protections and the availability or comparability of public information.
The offering
Offering and use of proceeds
vVARDIS is offering 9,722,223 Class A ordinary shares at an assumed IPO price of $18.00 per share. Estimated net proceeds are approximately $154.5 million, increasing to $178.9 million if the underwriters exercise their 1,458,333-share over-allotment option in full. The company plans to use the proceeds for general corporate purposes, including working capital, operating expenses and capital expenditures. Acquisitions or strategic investments are also possible, but vVARDIS has no current material agreements or commitments for them.
Shares outstanding and potential dilution
| Share count | No over-allotment | Full over-allotment |
|---|---|---|
| Class A shares expected outstanding after the offering | 38,594,629 | 40,052,962 |
| Class B voting-rights shares expected outstanding after the offering | 143,888,790 | — |
The post-offering Class A count includes offering shares and shares resulting from certain RSUs vesting at closing and certain option exercises. It excludes the following potential shares:
| Potential Class A shares | Amount | Terms |
|---|---|---|
| Outstanding RSUs | 1,591,901 | Issuable upon vesting |
| Warrants | 2,516,883 | Weighted-average exercise price of CHF 0.006 ($0.007) |
| Equity incentive plans | 1,838,339 | Reserved for issuance |
| Class B preferred holders’ anti-dilution rights | 5,925,847 | Subscribable at par based on the $18.00 IPO price; entitlement depends on the IPO price |
The equity incentive plans also reserve 5,000,000 Class B shares.
Voting control and governance
Class B shares carry ten times the voting power of Class A shares on a capital-invested basis. Founders will beneficially own all Class B shares and are expected to hold 86.9% of combined voting power immediately after the offering, assuming no over-allotment. This gives them control over substantially all shareholder votes, including director elections and major transactions.
Class B shares generally may be held only by founders or qualifying founder-family entities; transfers to others require conversion to Class A. Certain individual-sunset events—such as a founder’s death or permanent incapacity, or falling below a specified ownership threshold—give the other founder a right of first refusal and trigger conversion of the affected founder’s remaining Class B shares into Class A on a ten-for-one basis.
Trading, capital returns and listing
The company and substantially all shareholders, officers and directors are subject to 180-day lockups; founders and affiliated entities are subject to 270-day lockups, subject to exceptions and underwriter consent.
vVARDIS has never paid cash dividends and does not expect to do so for the foreseeable future, intending to retain earnings to fund operations and expansion. Its Class A shares are listed on the NYSE under ticker VVVV.
Prospectus summary
Business performance
Revenue grew rapidly, while the company continued to report substantial operating and net losses. H1 2026 operating loss narrowed year over year, but FY 2025 operating and net losses worsened compared with FY 2024.
| Results ($M) | H1 2026 | H1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| Net revenue | $28.558 | $9.088 | $30.209 | $12.157 |
| Cost of goods sold | $3.885 | $4.417 | — | — |
| Research and development | $7.159 | $2.002 | — | — |
| Selling, general and administrative | $35.064 | $26.750 | $59.925 | $32.213 |
| Operating loss | $(17.550) | $(24.081) | $(42.084) | $(30.966) |
| Net loss | $(27.807) | $(32.057) | $(56.447) | $(34.737) |
| Interest expense | $9.015 | $4.061 | $11.753 | $3.942 |
H1 2026 revenue increased 214% year over year; FY 2025 revenue increased 148%. Higher FY 2025 SG&A was a principal factor in the wider annual operating loss. Financing-related costs also increased: H1 2026 included $1.205M of losses on loans measured at fair value and $1.580M of term-loan extinguishment losses; FY 2025 included $1.647M and $1.628M, respectively. H1 2026 also included a $1.613M gain on loan conversion.
| Adjusted EBITDA loss ($M) | Current period | Prior period |
|---|---|---|
| H1 2026 / H1 2025 | $(10.550) | $(16.116) |
| FY 2025 / FY 2024 | $(23.442) | $(21.556) |
Adjusted EBITDA loss improved in H1 2026 but worsened in FY 2025. The reconciliation includes add-backs such as share-based compensation of $4.007M in H1 2026 and $13.884M in FY 2025. The company cautions that this non-GAAP measure excludes expenses and gains, may not be comparable across companies, and does not reflect capital expenditure needs.
IPO pro forma balance sheet and share structure
At June 30, 2026, the IPO-related pro forma adjustments materially reduced the reported shareholders’ deficit. The offering-adjusted presentation assumes the sale of 9.722223M Class A shares at $18 per share, after underwriting discounts and estimated expenses.
| Balance-sheet measure ($M) | Actual | Pro forma | Pro forma as adjusted |
|---|---|---|---|
| Cash | $28.974 | $29.017 | $183.549 |
| Total assets | $104.803 | $104.846 | $259.378 |
| Total liabilities | $164.408 | $132.999 | $132.999 |
| Shareholders’ equity (deficit) | $(118.502) | $(28.153) | $126.379 |
Pro forma loss per share was $0.55 for Class A and $0.06 for Class B in H1 2026; for FY 2025, it was $1.54 and $0.15, respectively. Pro forma weighted-average shares were:
| Weighted-average shares (M) | H1 2026 | FY 2025 |
|---|---|---|
| Class A | 35.760 | 28.196 |
| Class B | 143.889 | 143.889 |
Pro forma adjustments include 5.926M Class A shares for Class B preferred holders’ anti-dilution rights and 383,285 shares from RSU settlement and option exercises. The FY 2025 pro forma loss includes $9.287M of non-recurring share-based compensation for awards vesting in connection with the offering; another 161,661 RSUs expected to vest in connection with the offering are excluded from the pro forma calculations. Class B shares have one-tenth the economic participation rights of Class A shares. Founders’ shares convert into ten Class B voting-rights shares per ordinary share, increasing voting control while preserving aggregate economic participation.
Customer purchasing activity
U.S. dental practices placing more than one product order in the prior four months increased to 11,158 in Q3 2026 from 6,427 in Q3 2025, up 74% year over year. Growth slowed from 106% in Q1 2026 to 79% in Q2 and 74% in Q3; reported year-over-year growth had declined from 242% in Q1 2025 to 151% in Q4 2025.
Risk factors
Risk factors
Commercial adoption, customers and distribution
VVVV’s growth depends on adoption of Curodont®, a peptide-based, non-invasive treatment for early-stage cavities that challenges established drilling-and-filling practices. Dentists may be skeptical, and clinical outcomes may take six months or more to assess, lengthening sales cycles. Adoption also depends on education, clinical evidence, reimbursement, pricing, ease of use, regulatory clearance and competition, including fluoride treatments and new remineralization technologies. Reimbursement may be limited for minimally invasive treatments. Market-size estimates rely on uncertain assumptions; in particular, using one application for multiple neighboring cavities could reduce product utilization and the addressable market.
| Concentration metric | Current period | Prior period |
|---|---|---|
| Henry Schein share of sales | 72% in 2025 | 70% in 2024 |
| Heartland share of sales through Henry Schein | 31% in 2025 | 51% in 2024 |
| DSO share of products sold by distributors | 60% in six months ended June 30, 2026 | 60% in 2025; 65% in 2024 |
| Two distributors’ share of gross accounts receivable | 94% at June 30, 2026 | 68% at December 31, 2025; 63% at December 31, 2024 |
Henry Schein has exclusive U.S. dental-market distribution rights subject to new-customer thresholds due December 31, 2027 (with a cure-period extension to June 30, 2028) and December 31, 2028, and U.K. exclusivity through December 31, 2026. Its agreement is scheduled to expire December 31, 2029, then renew annually unless terminated. Fixed prices until January 1, 2027 restrict VVVV’s ability to pass through cost increases; a lowest-price provision also limits pricing flexibility. Distributors have no minimum-purchase obligations, and their order timing and inventory changes can distort revenue. Losing Henry Schein could make transition to other distributors or direct sales costly and uncertain. Distributor concentration, limited visibility into end-customer demand and DSO purchasing power create risks of lower sales, discounts and delayed payment. Most 2024 and 2025 revenue came from the U.S.; international expansion adds authorization, reimbursement, distribution, currency and compliance challenges.
Operations, margins, clinical evidence and product risks
VVVV relies on third parties for peptide materials and manufacturing, sterilization, packaging, assembly, warehousing and logistics; a single counterparty supports certain key manufacturing activities. Supplier changes may require costly qualification, validation and regulatory steps. Capacity, quality, storage or shipping failures could interrupt supply, delay launches, cause recalls or increase costs. Uncertain demand and long lead times also create risk of inventory shortages or obsolete and expired stock. Lower prices, unfavorable product mix, distributor discounts, manufacturing and freight costs, tariffs, reserves and quality or regulatory costs may pressure gross margins, particularly where costs cannot be passed on.
Clinical development depends on investigators, CROs and study sites whose recruitment, protocol compliance, data quality and follow-up VVVV cannot fully control. Delayed or inadequate studies could hinder regulatory submissions, claims, reimbursement and commercialization. Product-liability claims, recalls, safety concerns, counterfeit or improperly handled products, and negative publicity could damage clinical trust and adoption. Curodont® Repair Fluoride Plus also faces adverse perceptions or regulatory changes concerning fluoride. Competition, technological change and lower-priced alternatives may reduce demand and market share.
Regulation, legal and intellectual-property exposure
Products face differing FDA, EU MDR and Swiss requirements, including clinical evidence, quality systems and post-market surveillance. Classification changes could require additional data, submissions or controls; FDA could determine that Curodont® Repair Fluoride Plus is a combination product or does not comply with the OTC monograph. EU and Swiss requirements apply separately, and notified-body capacity may delay certification. Changes to U.S. OTC monographs and expanded cosmetics requirements under MoCRA may require new data, reformulation, relabeling or approvals. Noncompliance or unsupported marketing claims could lead to recalls, restrictions, fines or litigation.
Healthcare fraud-and-abuse, privacy, anti-corruption and environmental rules constrain commercial activity and third-party relationships. GDPR penalties can reach €20 million or 4% of prior-year worldwide annual turnover, whichever is greater; U.K. GDPR penalties can reach £17.5 million or 4% of annual global revenue, whichever is greater. Patent applications may be rejected, narrowed or challenged; third-party rights could require costly licenses or prevent commercialization. U.S. patent applications for Curodont® Protect have not issued, and the version marketed outside the U.S. relies on trade secrets without patent applications. Trade-secret, trademark and open-source software disputes could also impair commercialization.
Financial condition, controls and funding
| Financial risk metric | Current period | Prior period |
|---|---|---|
| Net loss | $27.8M in H1 2026 | $32.1M in H1 2025 |
| Net loss | $56.4M in FY 2025 | $34.7M in FY 2024 |
| Accumulated deficit | $256.3M at June 30, 2026 | — |
| Total loans | $84.2M at June 30, 2026 | — |
| Goodwill and intangible assets, net carrying value | $42.2M at June 30, 2026 | — |
VVVV expects significant expenses and losses for the foreseeable future and may never achieve profitability. It has no committed external funding source; unavailable or unfavorable financing could require cuts to development or commercialization. Debt service and covenants may constrain operations. An April 2026 amendment waived a violation related to failure to meet a $5.0M ordinary-share financing requirement; a September 2026 amendment waived further covenant violations linked to liquidation of two subsidiaries as of June 30, 2026.
Management concluded internal control over financial reporting was not effective at December 31, 2025, citing weaknesses in risk assessment, legacy ERP IT controls and business-process controls, including net revenue controls. A new ERP was implemented in Q4 2025; remediation work during 2026 had not yet established effectiveness, and testing was expected in connection with the FY2026 audit. Impairment of goodwill or intangibles could result from weaker forecasts, customer losses or regulatory and commercial setbacks. Tax attributes may go unused; tax disputes and OECD Pillar Two’s 15% minimum effective rate could increase taxes and compliance costs. VVVV does not maintain a comprehensive FX-hedging program.
Cybersecurity, people and external events
Cyber incidents affecting VVVV or vendors could expose data, disrupt systems and shipments, and cause remediation costs, litigation or regulatory action; past incidents have not materially adversely affected the company, but future impact is uncertain. AI use in R&D, analytics, marketing and operations—and third-party diagnostic tools used by dental professionals—creates risks involving inaccurate outputs, privacy, IP, liability and evolving regulation. Growth also depends on recruiting and retaining specialized personnel; founders and Co-CEOs Haley and Goly Abivardi are central to strategy. Macroeconomic weakness may reduce elective dental procedures, while geopolitical events, tariffs, sanctions, labor disruptions, pandemics and natural disasters could impair demand and supply chains.
Ownership, offering and shareholder risks
Following the offering, founders are expected to hold approximately 86.9% of voting power and 54.9% of economic interest; insiders collectively approximately 87.1% and 55.9%, respectively. Class B shares carry ten times the voting power of Class A on a capital-invested basis. Separately, the co-founders’ CHF 105.0M (approximately $127.916M) personal loans are secured by 10.329M shares. After described refinancing, pledged shares could total 14.942M securing loans of up to CHF 160.0M (approximately $194.920M). Default and foreclosure could pressure the share price and change control. New loan terms include substantial fees, 15% annual interest on one loan and make-whole repayments of 140% or 160% of principal on another.
There was no established public market before the IPO; lock-up expirations, potential issuance of 4.109M shares from outstanding instruments and limited analyst coverage may pressure trading and liquidity. IPO investors face stated immediate net tangible book value dilution of $16.55 per share ($16.18 with full over-allotment) against the $18.00 IPO price. VVVV does not expect to pay dividends. Swiss governance and takeover rules, dual-class voting and potential reliance on controlled-company exemptions may limit public shareholders’ influence and protections.
Use of proceeds
Use of IPO Proceeds
At the $18.00-per-share offering price, the company estimates net IPO proceeds of $154.5 million, after underwriting discounts, commissions and estimated offering expenses. Net proceeds would be approximately $178.9 million if the underwriters fully exercise their over-allotment option.
The company intends to use the proceeds for general corporate purposes, including working capital, operating expenses and capital expenditures. The IPO is also intended to establish a public market for its Class A ordinary shares and improve access to public equity markets for the company and its shareholders.
Until the proceeds are used, the company expects to invest them in short-term, interest-bearing investment-grade securities, certificates of deposit or government securities. Planned allocations may change, and management has broad discretion over how the proceeds are used, creating a risk that the funds may not be applied effectively.
Dividend policy
Dividend policy
The company has never declared or paid cash dividends on its ordinary shares and intends to retain future earnings to fund its operations and expansion. It does not expect to pay dividends for the foreseeable future. Any future dividend would be at the board’s discretion and subject to applicable law, the company’s financial condition and operating results, capital requirements, contractual restrictions, and other relevant factors.
Under Swiss law, shareholders must approve dividends, and the auditors must confirm that the board’s proposal complies with Swiss statutory law and the company’s articles. Dividends may be paid only from distributable profits or reserves shown in the audited Swiss-law standalone statutory balance sheet, after required allocations to reserves. A distribution from share capital requires a reduction of share capital.
Accordingly, investors should not expect dividend income; their return will depend on appreciation in the share price.
Capitalization
Capitalization and offering
As of June 30, 2026, vVARDIS had $84.207M of loans and a total shareholders’ deficit of $118.502M. The pro forma conversion reclassified the embedded derivative liability and preferred shares into equity accounts, but changed total capitalization only slightly. The assumed IPO would provide estimated net proceeds of $154.5M and turn shareholders’ equity positive.
| Capitalization item | Actual June 30, 2026 | Pro forma | Pro forma as adjusted |
|---|---|---|---|
| Cash and cash equivalents | $28.974M | $29.017M | $183.549M |
| Non-current derivative liability | $31.409M | — | — |
| Loans | $84.207M | $84.207M | $84.207M |
| Mezzanine equity | $58.897M | — | — |
| Shareholders’ equity (deficit) | $(118.502)M | $(28.153)M | $126.379M |
| — Attributable to vVARDIS Holding AG / owners | $(117.292)M | $(26.943)M | $127.589M |
| — Non-controlling interest | $(1.210)M | $(1.210)M | $(1.210)M |
| Total capitalization | $56.011M | $56.054M | $210.586M |
The $31.409M embedded derivative liability was reclassified to additional paid-in capital (APIC), and $58.897M of preferred shares was reclassified from mezzanine equity to share capital and APIC. Pro forma accumulated deficit is $265.609M, compared with $256.322M actual. Pro forma adjustments also recognize $9.3M of incremental share-based compensation expense for 268,139 RSUs and 486,552 options under the 2024 and 2025 plans that vest in connection with the offering; this increases both accumulated deficit and APIC. The adjustments include settlement or exercise of awards through issuance of 383,285 Class A ordinary shares. The small increase in total capitalization from actual to pro forma primarily reflects the $43K par-value payment for anti-dilution shares; the conversion and compensation adjustment are principally reclassifications within capitalization.
Offering, share structure and dilution
The offering assumes the sale of 9,722,223 Class A shares at $18.00 per share, with estimated net proceeds of $154.5M after underwriting discounts, the financial advisory fee and estimated offering expenses.
The conversion establishes a dual-class structure. Founders’ 14,388,879 Class A shares convert into 143,888,790 Class B voting-rights shares, each carrying 10 votes. Class B preferred holders also receive 5,925,847 additional Class A shares under contractual anti-dilution rights, calculated using the assumed $18.00 IPO price, in exchange for aggregate par value of $43K.
| Shares outstanding | Pro forma | Pro forma as adjusted |
|---|---|---|
| Class A ordinary shares | 34,692,058 | 44,358,815 |
| Class B voting-rights shares | 143,888,790 | 143,888,790 |
The share counts above exclude further potential dilution from:
- 161,661 RSUs to be granted under the 2026 plan that vest in connection with the offering;
- 1,591,901 shares issuable upon vesting of RSUs;
- 2,516,883 shares issuable upon outstanding warrants, with a weighted-average exercise price of CHF 0.006 (or $0.007); and
- Remaining 2026 plan capacity for 1,838,339 Class A shares and 5,000,000 Class B voting-rights shares.
The filing states there were no other material capitalization changes after June 30, 2026.
Dilution
Net tangible book value and IPO dilution
At June 30, 2026, historical net tangible book value was $(159.5) million, or $(4.67) per ordinary share, based on 34,186,620 ordinary shares outstanding. This measure excludes goodwill and other intangible assets, liabilities and mezzanine equity, and non-controlling interests.
The pro forma conversion reclassifies $58.9 million of preferred-share carrying value from mezzanine equity to share capital and additional paid-in capital, and $31.4 million of embedded derivative liability to additional paid-in capital. Other adjustments include 383,285 Class A shares issued upon RSU settlement and option exercise, and 5,925,847 Class A shares issued to Class B preferred holders under anti-dilution rights at par. After these adjustments, pro forma net tangible book value is $(69.1) million overall, including $(48.9) million attributable to Class A, or $(1.41) per Class A share, based on 34,692,058 Class A shares.
| IPO scenario | Class A shares sold | Gross proceeds | Adjusted net tangible book value attributable to Class A | Per-share book value | Dilution to IPO investors |
|---|---|---|---|---|---|
| Base offering at $18.00 per share | 9,722,223 | $175.0 million | $64.5 million | $1.45 | $16.55 per share |
| Full exercise of over-allotment option | — | — | — | $1.82 | $16.18 per share |
After underwriting discounts, commissions and estimated offering expenses, the base offering results in $85.4 million of adjusted net tangible book value overall, of which $64.5 million is attributable to Class A shares. The offering increases existing shareholders’ net tangible book value by $2.86 per Class A share. The base offering’s per-share calculation excludes 55,466 treasury shares.
Share ownership and consideration
| Holder group | Shares | Ownership | Consideration | Share of consideration | Average price per share |
|---|---|---|---|---|---|
| Existing shareholders | 49,025,471 | 83.5% | $194.7 million | 52.7% | $3.97 |
| IPO investors | 9,722,223 | 16.5% | $175.0 million | 47.3% | $18.00 |
| Total | 58,747,694 | 100.0% | $369.7 million | 100.0% | $6.29 |
Existing-shareholder consideration includes the anti-dilution shares issued to preferred holders for aggregate par value. If the over-allotment option is fully exercised, existing shareholders would own 81.4% of Class A shares.
The pro forma figures exclude awards granted after June 30, 2026, including 161,661 RSUs expected to vest in connection with the offering. Exercise or settlement of outstanding warrants, options and RSUs, and any future equity awards, would further dilute IPO investors.
A letter from our founders
Product opportunity and commercial progress
vVARDIS positions Curodont as a non-invasive biologic treatment for early-stage cavities, aiming to preserve natural tooth structure and fill a gap between prevention and drilling. The founders estimate a U.S. target addressable market of approximately $29B, including cavities they believe go undiagnosed among the 35%–37% of the U.S. population that does not currently visit a dentist. They cite tooth decay as affecting approximately 2.5B people globally and an estimated 75%–85% of the U.S. population.
Since its U.S. launch in January 2024, Curodont has been sold into more than 20,000 U.S. dental practices and applied to over 3.5M teeth. The founders describe revenue growth as rapid and the business as asset-light with “exceptional gross margins,” but provide no amounts or rates to quantify revenue, growth, or margins.
Growth strategy and adoption
The company aims to build a broader healthcare platform drawing on its intellectual property, scientific expertise, and accumulated know-how. Its stated priorities include continued investment in R&D, clinical evidence, and the capabilities needed for long-term growth. The founders also see AI-powered cavity detection as an opportunity to expand the addressable market.
The letter emphasizes that changing clinical practice takes time. Broader adoption depends on demonstrating treatment effectiveness, educating clinicians and building their confidence, establishing practical implementation pathways, and increasing patient awareness. Accordingly, the estimated market opportunity is not equivalent to realized demand, and commercial success depends on converting awareness and interest into sustained use.
Founder control and financial visibility
The founders say they will retain voting control after the offering through a dual-class share structure, citing their long-term commitment. The letter provides no quantified financial results with which to assess the company’s current revenue scale, profitability, cash flow, balance sheet, or margins.
Management's discussion and analysis
Business and commercial performance
VVVV is a single-segment company commercializing peptide-based Curodont® treatments for early-stage cavities. Its flagship U.S. product, Curodont® Repair Fluoride Plus, drives the vast majority of revenue; Curodont® Repair is sold in other markets. The treatment is designed to be drill-free and needle-free, administered chairside in five minutes or less, and used without anesthesia or specialized equipment. Since its January 2024 U.S. launch, the products had treated more than 3.5 million teeth by June 30, 2026. Flagship products had been sold to more than 20,000 of approximately 110,000 U.S. general dental practices.
VVVV sells through distributors, with Henry Schein exclusive in the U.S. Its U.S. hybrid model combines direct sales and clinical education with Henry Schein’s distribution network. It is piloting in-office and direct-to-patient marketing to stimulate patient demand but does not plan to sell directly to consumers. Repeat purchasing continues to expand, though growth has moderated:
| U.S. recurring buying practices* | 2026 count | Year-over-year growth |
|---|---|---|
| Q1 | 7,615 | 106% |
| Q2 | 8,461 | 79% |
| Q3 | 11,158 | 74% |
*Practices with more than one order in the preceding four months.
Financial results
Revenue growth in the six months ended June 30, 2026 (H1 2026) was concentrated in the U.S. and in the flagship product. The U.S. contributed $19.2M of the $19.5M increase: $17.6M from higher Curodont® Repair Fluoride Plus volume and $1.6M from favorable pricing. The U.K. and Italy added $0.4M and $0.3M, while Switzerland declined $0.3M and other countries declined $0.1M.
| H1 results ($M) | H1 2026 | H1 2025 |
|---|---|---|
| Net revenue | $28.558 | $9.088 |
| Cost of goods sold | $3.885 | $4.417 |
| Gross profit | $24.673 | $4.671 |
| R&D expense | $7.159 | $2.002 |
| SG&A expense | $35.064 | $26.750 |
| Operating loss | $(17.550) | $(24.081) |
| Interest expense | $9.015 | $4.061 |
| Loss before tax | $(28.157) | $(32.030) |
| Income tax benefit (expense) | $0.350 | $(0.026) |
| Net loss | $(27.807) | $(32.057) |
| Adjusted EBITDA loss (non-GAAP) | $(10.550) | $(16.116) |
Gross margin was 86.4%, supported by lower manufacturing costs despite higher sales. The third-generation manufacturing process, launched in mid-2025, reduced average cost per box of the flagship product from $88.7 in H1 2025 to $20.3 in H1 2026. Lower manufacturing and logistics costs more than offset volume-related costs and higher excess and obsolescence charges. Management expects cost of goods sold to rise with unit sales but remain relatively stable as a share of revenue over the long term; margins remain sensitive to product mix, manufacturing, freight and supply-chain conditions.
R&D spending increased mainly to support peptide-process changes, GMP qualification and a second peptide source. SG&A growth reflected commercial hiring and related share-based compensation, other commercial costs, marketing, financing- and IPO-related consulting and legal costs, and depreciation and amortization. Management expects both R&D and SG&A to increase as it develops the platform and supports growth; commercial spending may precede revenue benefits.
Financing costs remain significant. Interest expense increased mainly because the 2030 Term Loan Tranche II was outstanding throughout H1 2026. Other H1 items included a $1.205M fair-value loan loss (versus $1.474M), a $1.613M gain on loan conversion, an $8,000 derivative fair-value loss, and a $1.580M term-loan extinguishment loss (versus $1.245M). The 2027 Convertible Loan converted to equity in April, ending its future fair-value remeasurement. A full valuation allowance is maintained against deferred tax assets, including tax-loss carryforwards.
For FY 2025, revenue was $30.209M versus $12.157M in FY 2024, while net loss widened as commercial investment and financing costs increased:
| FY results ($M) | FY 2025 | FY 2024 |
|---|---|---|
| Net revenue | $30.209 | $12.157 |
| Cost of goods sold | $7.792 | $8.269 |
| R&D expense | $4.575 | $2.641 |
| SG&A expense | $59.925 | $32.213 |
| Operating loss | $(42.084) | $(30.966) |
| Interest expense | $11.753 | $3.942 |
| Net loss | $(56.447) | $(34.737) |
| Adjusted EBITDA loss (non-GAAP) | $(23.442) | $(21.556) |
Cash, debt and liquidity
| Cash flows ($M) | H1 2026 | H1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| Operating cash flow | $(16.317) | $(22.755) | $(16.333) | $(23.797) |
| Investing cash flow | $0 | $(0.247) | $(2.805) | $(0.325) |
| Financing cash flow | $29.924 | $31.975 | $31.978 | $27.134 |
H1 2026 operating cash use reflected a $27.8M net loss, $14.6M of noncash adjustments and a $3.2M working-capital outflow, including higher receivables and prepaids partly offset by higher liabilities and accrued expenses. FY 2025 operating cash flow benefited from stronger collections, including a $15.0M deferred-revenue inflow from a Henry Schein prepayment. H1 2026 financing inflow was mainly $31.7M of Series B preferred-share proceeds, less issuance costs and loan repayments. Investing outflow was limited in H1 after substantial completion of ERP and CRM implementation in 2025.
| Cash and debt ($M) | June 30, 2026 | Comparison |
|---|---|---|
| Cash and cash equivalents | $29.0 | $17.5 at Dec. 31, 2025 |
| Loan carrying value | $84.207 | $99.817 at June 30, 2025; $104.600 at Dec. 31, 2025 |
| Current debt maturities | $17.204 | — |
| Non-current debt | $67.003 | — |
Loan carrying value was net of $25.607M of unamortized discounts and issuance costs. The 2030 Term Loans are secured by substantially all company and subsidiary assets and guaranteed by the parent and certain subsidiaries. Effective rates at June 30, 2026 were 24.6% on Tranche I and 31.8% on Tranche II, up from 19.8% and 26.8% at December 31, 2025. A 100-basis-point increase in one-month Term SOFR would raise annual interest expense by $0.9M; the company does not hedge interest-rate exposure.
Scheduled principal contractual obligations at December 31, 2025 were approximately $122.428M, including $119.792M of borrowings and $2.636M of lease liabilities. The loan agreement includes a minimum-liquidity covenant and restrictions on additional debt, liens, asset sales and investments. VVVV obtained covenant waivers or consents, including a waiver related to liquidation of two subsidiaries that extends through March 14, 2027; it reported no other existing events of default as of the prospectus date. Continued losses, growth investment, working-capital needs and debt service could require additional equity, debt or strategic financing.
Principal risks and controls
Adoption depends on educating practitioners, patients, payors and government bodies about a new treatment and changing established protocols. Repeat orders, account penetration and retention are important; weaker utilization, customer attrition or less effective distributor execution could constrain growth. Broader reimbursement and guideline recognition could support adoption. Clinical evidence, new indications and supply-chain capacity require investment and may face scientific, regulatory or commercialization delays. Economic weakness could also lead patients to defer dental care and practices to reduce purchases.
Customer concentration is material: one customer represented $6.7M, or 93%, of accounts receivable at June 30, 2026, compared with $1.7M, or 51%, at June 30, 2025. U.S.-dollar debt held by Swiss-franc-functional subsidiaries creates earnings volatility; a hypothetical 10% U.S.-dollar strengthening (weakening) would have increased (decreased) H1 2026 loss from operations by $6.8M. VVVV does not hedge foreign-exchange risk.
Management concluded internal control over financial reporting was not effective as of December 31, 2025, citing weaknesses in risk assessment, the control environment and information systems, including legacy ERP controls and system-generated reports. During 2026 it implemented an updated risk-control framework, ERP IT controls, revised business-process controls and monthly-close controls, but the weaknesses were not yet considered remediated; testing is expected in connection with the FY 2026 audit. Additional control-related costs are expected, and remediation is not assured. As an emerging growth company, VVVV elected the JOBS Act extended transition period for adopting new accounting standards and is eligible for specified reporting and auditor-attestation exemptions, subject to statutory conditions.
Business
Business and commercial progress
vVARDIS is building a market for Curodont®, its peptide-based treatment for early, non-cavitated cavities (ICDAS 1–2). The company says its P11-4 peptide supports mineral formation within lesions, aiming to arrest or reverse early decay while preserving tooth structure. Treatment is designed to be chairside, drill- and needle-free, and completed in five minutes or less. The products are not intended for more advanced decay that may require conventional restorative treatment.
| Commercial and financial measure | Current period | Prior-period comparison |
|---|---|---|
| Net revenue | FY2025: $30.2 million | Up 148.5% year over year |
| Gross profit / gross margin | FY2025: $22.4 million / 74.2% | — |
| Net revenue | H1 2026: $28.6 million | Up 214.2% year over year |
| Gross profit / gross margin | H1 2026: $24.7 million / 86.4% | — |
| Net loss | H1 2026: $27.8 million | — |
The company attributes its high gross margins partly to an asset-light model. Despite rapid growth, it remains loss-making; its accumulated deficit was $256.3 million at June 30, 2026.
Since its January 2024 U.S. launch, the company estimates its products had treated more than 3.5 million teeth by June 30, 2026. Its flagship products had been sold to more than 20,000 U.S. practices—about 15% of private practices and 65% of DSOs, according to the company. The U.S. is its near-term priority, with additional activity in the U.K. and selected European markets. In the U.S., Henry Schein distributes and fulfills orders, while vVARDIS’s team drives practice acquisition, education and repeat use. At September 30, 2026, that team included 68 key account managers, 9 internal sales representatives, 9 clinical education specialists and 12 marketing staff.
Awareness remains limited, so growth depends on clinician and patient education, detection of early lesions, and reimbursement access. The company works with more than 50 U.S. and European dental-school programs, and is developing clinician advocacy, in-office marketing and patient outreach. Curodont Repair Fluoride Plus is billable under CDT code D2991; the company reports partial Medicaid coverage in 11 states and coverage by 9 commercial insurers. Collaborations with VideaHealth, Pearl and Henry Schein One aim to connect AI detection with treatment planning. The company estimates AI could increase early-cavity identification by 30%–40%; early pilot practices reportedly completed about three times as many Curodont treatments with AI-enabled diagnostic solutions.
Market opportunity and evidence
vVARDIS estimates 900 million–1 billion untreated early-stage cavities in the U.S., implying a theoretical $29 billion total addressable market. Its narrower serviceable market is at least 450 million cavities, or at least $13 billion, among patients who visit a dentist and whose lesions are identified and managed. These estimates rely on assumptions about diagnosis, access and treatment acceptance; they are not realized demand. The company positions Curodont between prevention and invasive “drill-and-fill” treatment, where early lesions may otherwise be monitored or treated invasively.
The company cites more than 250 publications, including clinical trials and observational studies. Examples include a retrospective pediatric cohort in which 93% of 405 lesions showed no progression at last follow-up, and randomized studies reporting greater lesion regression or inactivation than fluoride-based comparators. Results vary by study and product generation; some research was company-funded or involved company employees or paid investigators. Some studies did not assess adverse events, and in-vitro findings are not clinical outcome evidence. The filing also emphasizes that the FDA has not made a product-specific safety or efficacy determination for the U.S. OTC-monograph product.
Development, competition and execution risks
The company sees no currently commercialized direct competitor for its claimed non-invasive restorative use in early-stage cavities. Alternatives include fluoride varnish, silver diamine fluoride, monitoring and invasive procedures. This is the company’s assessment; clinicians may continue to favor existing approaches, and competitors or changing standards of care could weaken its position. R&D focuses on the P11-4 platform, additional indications, later-stage cavities, and hard- and soft-tissue applications. The company had approximately 11 R&D employees at June 30, 2026.
vVARDIS relies on third parties for substantially all manufacturing and supply-chain stages. Specialized peptide supply and certain materials or manufacturing activities involve single providers, generally without long-term exclusive supply agreements. Limited access to qualified alternatives creates continuity and scaling risks as demand grows.
Henry Schein has exclusive U.S. distribution rights for Curodont Repair Fluoride Plus and Curodont Protect, subject to minimum new-customer thresholds, and exclusive U.K. rights for Curodont Repair and Protect through December 31, 2026. The agreement runs through December 31, 2029, with automatic one-year renewals absent timely notice. Henry Schein previously prepaid an amount in the mid-teens of millions of U.S. dollars; the credit applies to purchases from July 1, 2026, up to the mid-single-digit millions of U.S. dollars per quarter. Specified termination, breach or delivery events can require accelerated repayment of uncredited amounts.
Regulation, intellectual property and other risks
Curodont Repair Fluoride Plus is marketed in the U.S. as an OTC drug under FDA Anticaries Monograph M021; it has no product-specific NDA or ANDA approval. Changes to monograph requirements or regulatory interpretation could require new evidence, relabeling, reformulation or premarket review. Curodont Repair is a Class IIa medical device in the EU and Switzerland, with EU CE marking since January 2012; ongoing access depends on MDR compliance, certification and clinical evidence. Switzerland has separate registration and surveillance requirements. Product classification and requirements may also differ across markets.
As of June 30, 2026, vVARDIS reported 7 issued and 5 pending U.S. patents, 76 issued foreign national patents and 102 pending foreign national patent applications across 39 jurisdictions. Material patent coverage is expected to expire from 2033 to 2047. The company had approximately 153 employees, up from 137 at December 31, 2025. It also faces healthcare-compliance, privacy, cybersecurity, environmental and distributor-oversight risks. It leases its facilities and reported no litigation it believed would materially affect the business.
Management
Management, compensation and governance
Leadership and board
Co-founders and sisters Haley and Goly Abivardi serve as Co-CEOs and Co-Chairs. Haley leads commercial strategy, global growth, business development, finance, market access and partnerships; Goly leads strategy, innovation, clinical development, operations and quality, with a focus on scientific leadership and clinical adoption. CFO and Chief People Officer Thomas Rondot has held his role since 2021 and previously held senior finance and corporate development positions at Coty and Danone. The leadership team and board bring experience in dental services, oral care, medical devices, healthcare operations and healthcare finance.
Before completion of the NYSE offering, the board is expected to have seven members. Three incoming directors—Elizabeth Coddington, Steve Swift and Frank Williams—are identified as independent under NYSE rules. The Audit Committee is planned to comprise Swift (chair), Williams and Coddington; all are stated to meet applicable independence and financial-literacy requirements, and Swift is the designated audit committee financial expert. Juergen Stark (chair), Swift and Williams will serve on the Nomination and Compensation Committee. Directors serve one-year terms, with the first public-company annual meeting expected in 2027.
Compensation and equity incentives
| FY2025 compensation | Amount |
|---|---|
| Directors’ aggregate compensation accrued or paid | $5.0245M |
| Executive officers’ aggregate compensation | $3.7424M |
| Executive share-based compensation, at grant-date fair value | $1.7370M |
| Executive pension, retirement or similar benefits accrued or set aside | $253,966 |
As of June 30, 2026, the 2024 Equity Incentive Plan had 1.572117M RSUs outstanding and no shares remaining available for issuance. The 2024 and 2025 Option Plans had 163,010 and 22,500 options outstanding, respectively, or 185,510 in total. No further awards will be granted under the prior plans after the 2026 Plan takes effect. Most outstanding unvested RSUs and restricted shares are generally expected to vest in connection with the offering, subject to continued service.
Adopted October 1, 2026, the 2026 Plan will be the sole vehicle for new equity awards after the offering. It initially reserves 2.0M Class A ordinary shares and 5.0M Class B voting-rights shares. Starting in fiscal 2027, annual increases may be made subject to plan limits, including up to 5% of each class outstanding at the prior fiscal year-end. The company expects to seek shareholder approval for increases to conditional share capital to support future awards; no more than 2.0M shares may be issued for incentive stock options. The plan has a ten-year term unless ended earlier.
The plan permits options, share appreciation rights, restricted shares and units, performance awards and other share-based awards. On a change in control, awards generally accelerate vesting and convert to cash based on the transaction’s per-share consideration, less the exercise price for options or SARs, subject to committee discretion and alternative treatment. This could create transaction-related compensation obligations. Certain executive agreements provide salary, short-term incentives, equity opportunities and benefits, and one-year post-termination noncompete and nonsolicitation covenants; noncompete compensation may be up to one year’s base salary, reduced by subsequent income. The company adopted a clawback policy for incentive compensation following specified accounting restatements.
Governance and shareholder protections
The company intends to follow Swiss home-country practices instead of certain NYSE governance requirements, including requirements for a majority-independent board, fully independent nomination and compensation committees, independent-director executive sessions, certain shareholder-meeting quorum rules and shareholder approval of certain securities issuances, including share-option plans. Its articles authorize certain share issuances without renewed shareholder approval and Class B voting-rights shares for founders under employee plans. The company cautions that shareholders will not receive all protections available under NYSE standards.
The founders and other controlling shareholders are expected to retain majority voting power after the offering and the ability to nominate a majority of directors. If the company ceases to qualify as a foreign private issuer, it intends to rely on the NYSE controlled-company exemption, which can permit a non-independent board majority and a committee that is not fully independent. Audit Committee independence requirements continue to apply, with NYSE rules allowing a phase-in to a fully independent committee within one year of listing. The company expects to remain a foreign private issuer and will reassess its status annually after its second fiscal quarter; loss of that status depends on U.S. ownership of voting power exceeding 50% and specified U.S. business contacts.
Beginning with the 2027 annual meeting, Swiss law will require binding shareholder votes on maximum aggregate director and executive compensation. The board must also issue an annual auditor-reviewed compensation report; a nonbinding shareholder vote is required if variable compensation is approved prospectively.
Comparison of swiss corporate law and u s corpor
Swiss and Delaware corporate-law comparison
The comparison reflects Swiss law and the company’s Amended and Restated Articles of Association and related governance documents, as expected to take effect immediately before completion of the offering.
Shareholder decisions and corporate transactions
- Major transactions: Swiss mergers, demergers and sales of all or substantially all assets generally require approval by two-thirds of the voting rights represented at the meeting and a majority of the par value represented. Delaware generally requires board approval and approval by a majority of outstanding shares entitled to vote. Participants in a Swiss merger or demerger may sue if the consideration is inadequate and seek additional value. A merger providing only cash compensation requires approval by at least 90% of eligible voting members of the transferring entity.
- Dissolution and amendments: Swiss dissolution generally requires two-thirds of represented voting rights plus a majority of represented par value; Delaware generally requires unanimous shareholder approval unless the board initiates dissolution, when a simple majority may suffice. Swiss amendments usually require a majority of represented voting rights, while specified fundamental changes require two-thirds plus a majority of represented par value. Swiss law has no equivalent to Delaware’s general three-year restriction on certain business combinations with a shareholder owning at least 15%.
- Shareholder participation: Swiss shareholders generally act through general meetings; written consent is available only if no shareholder requests a meeting. Holders of at least 5% of share capital or voting rights may request a meeting for specified matters. Holders of shares representing at least 0.5% of capital or voting rights may request agenda items, subject to lead-time requirements. Shareholders may propose candidates and matters within agenda items and request certain information or special examinations. Cumulative voting is prohibited in both jurisdictions.
Board governance, compensation and duties
- Listed Swiss companies must elect directors individually each year, as well as elect the chair(s) and compensation committee members; classified boards are prohibited. Swiss shareholders may remove directors with or without cause, but the company’s articles require a supermajority for removal. Delaware permits classified boards, and removal rules depend on the board structure and governing documents; directors of a classified board generally may be removed only for cause.
- Swiss shareholders have a binding, non-transferable vote on maximum aggregate compensation for the board, executive committee and any advisory boards. Future-period variable compensation is subject to an advisory vote. In Delaware, director compensation is generally determined by the board unless governing documents restrict it.
- Swiss boards retain specified non-transferable responsibilities, including overall management and supervision, financial-control systems, appointing management, reporting, and taking action in cases of over-indebtedness. Swiss directors and executives must disclose conflicts; courts generally limit review of properly prepared, informed and conflict-free business decisions. Delaware directors owe duties of care and loyalty to the corporation and its shareholders.
- Swiss law does not permit indemnification for intentional or grossly negligent breaches of corporate duties. The company’s articles provide indemnification to the extent permitted by law, and D&O insurance may cover negligence. Swiss shareholders may discharge directors and executives for known conduct, with limited effect on claims. Delaware permits specified indemnification and exculpation, subject to statutory exceptions, including loyalty breaches, intentional misconduct, unlawful distributions and improper personal benefits.
Information access, litigation and liability
- Swiss shareholders have more limited access to company records than under Delaware law. Holders of at least 5% of nominal share capital or voting rights may inspect books and records, subject to business-secrecy and other protected interests; information need only be provided if required to exercise shareholder rights. The board must decide within four months. A denial requires written reasons and may be challenged in court within 30 days. Shareholders may inspect only their own share-register entry.
- Shareholders may request general-meeting minutes within 30 days. The annual report, compensation report and auditor reports must be available at least 20 calendar days before the annual meeting, where shareholders may also request information from the board and external auditors.
- Delaware generally permits class and derivative actions for fiduciary-duty and other corporate claims. Swiss law does not provide class or derivative actions as such, although shareholders may bring certain claims against directors, officers or liquidators, including claims for harm to the company. U.S. class actions may remain possible where U.S. law and jurisdiction apply. Swiss fee recovery for a winning party is generally limited; a losing shareholder acting in good faith may sometimes recover fees.
Dividends and share issuance
- In Switzerland, the general meeting must approve dividends; the board may propose but cannot authorize them. Distributions are limited to prior- or current-year profits, carried-forward profits or distributable reserves, as shown in the audited Swiss statutory standalone balance sheet after required reserve allocations. Distributions from share capital require a capital reduction. In Delaware, the board may declare dividends from surplus or, absent surplus, current- or prior-year net profits, subject to the charter.
- Swiss share creation requires shareholder approval. Creating a capital range or conditional capital requires at least two-thirds of represented voting rights and a majority of represented par value; the articles may set higher thresholds. Within an approved capital range, the board may issue or cancel shares for up to five years, by up to 50% of current share capital in either direction. Conditional shares may be issued upon exercise of options or conversion rights granted to specified stakeholders. Delaware share creation is authorized by board resolution under authority in the certificate of incorporation.
- Swiss preferential voting shares, including the company’s Class B voting-rights shares, are not treated as preference shares under the cited rules.
Taxation
Taxation of Class A ordinary shares
Swiss taxes
- Withholding tax: Dividends and other taxable distributions are generally subject to 35% Swiss withholding tax on the gross amount. Repayment of par value and qualifying capital-contribution reserves are generally exempt. Swiss-resident private investors and domestic commercial shareholders may generally obtain a full refund or credit if they properly report the income. Non-Swiss residents may qualify for a full or partial refund under an applicable tax treaty, subject to its conditions and procedures.
- Stamp duties: The Company bears 1% issuance stamp duty on newly issued offering shares, net of certain deductions. Newly issued shares are not subject to securities-transfer stamp duty on delivery against payment. Sales of existing shares and later secondary-market transactions may incur transfer stamp duty of up to 0.15% of consideration when a Swiss or Liechtenstein bank or securities dealer is a party or intermediary and no exemption applies.
- Investor-level taxes: Non-residents generally owe no Swiss income tax on dividends or capital gains solely from holding the shares, and no Swiss wealth or annual capital tax solely from holding them. Swiss-resident private shareholders generally pay income tax on distributions; gains on third-party sales are generally tax-free private capital gains, while year-end share value is subject to cantonal and communal wealth tax. Domestic commercial shareholders generally treat distributions and disposal gains or losses as business income and may be subject to income and wealth or capital taxes. Qualifying corporate shareholders may receive participation relief, including where the market value is at least CHF 1 million.
- Information exchange: Switzerland has collected covered financial-account data under its AEOI regime since 2017 and exchanged it since 2018. A new Swiss-U.S. FATCA agreement signed June 27, 2024 would replace the current consent/group-request approach with mutual automatic exchange through the Swiss Federal Tax Administration. Swiss legislative changes are required; the stated target effective date is January 1, 2029.
U.S. federal tax considerations
The disclosure addresses eligible U.S. holders entitled to Treaty benefits who acquire shares in the offering and hold them as capital assets. The Company does not currently expect to pay distributions and does not intend to calculate U.S.-tax earnings and profits. U.S. holders should therefore generally expect distributions to be reported as dividends, even if some amount might otherwise be treated as a return of capital or capital gain. Dividends are generally foreign-source income; qualifying Swiss withholding may be eligible for a U.S. foreign tax credit, but withholding above the Treaty rate is not creditable. Gains or losses on share sales are generally capital, long-term if the shares are held for more than one year, and generally U.S.-source for foreign-tax-credit purposes.
PFIC risk and related compliance
The Company does not expect to be a passive foreign investment company (PFIC) in 2026 or the foreseeable future, based on its expected post-offering share price and anticipated income and asset composition, including goodwill. This assessment is uncertain: PFIC status is determined annually under passive-income and passive-asset tests, may change with share price and asset values, and could be challenged by the IRS. U.S. counsel gives no opinion on the Company’s PFIC status. If the Company is a PFIC during a holder’s ownership, PFIC treatment generally continues for that holder in later years even if the Company ceases to meet the tests, unless the holder makes an applicable election or recognizes gain.
PFIC consequences may also apply if the Company or an entity it owns is a lower-tier PFIC. U.S. holders may be taxed on certain lower-tier PFIC distributions and gains without receiving the related proceeds; a mark-to-market election for the Company’s shares does not cover lower-tier PFIC shares. Without a timely mark-to-market or qualified electing fund (QEF) election, gains and distributions exceeding 125% of average annual distributions over the prior three years (or the shorter holding period) may be allocated across the holding period, taxed partly at the highest applicable rate, and subject to an interest charge. A mark-to-market election is available only if the shares qualify as marketable—generally, more than a de minimis amount must trade on a qualified exchange at least 15 days in each calendar quarter; the NYSE is a qualified exchange. The Company does not intend to provide information needed for a QEF election. PFIC status may also eliminate preferential dividend tax rates for certain non-corporate U.S. holders.
U.S. holders with PFIC exposure generally must file annual IRS Form 8621, subject to exceptions. Certain holders may also have foreign-asset reporting obligations (identified in the filing as Form 8398); failure to file when required can trigger monetary penalties and extend the tax-return limitations period. Dividend and sale-proceeds payments through U.S. channels may be subject to information reporting and backup withholding, which is generally creditable against tax or refundable if required information is provided.
Underwriting
IPO underwriting and offering terms
The underwriters agreed to purchase 9,722,223 Class A ordinary shares, allocated as follows:
| Underwriter | Shares |
|---|---|
| Goldman Sachs | 3,402,778 |
| J.P. Morgan | 3,402,778 |
| William Blair | 1,652,778 |
| UBS | 972,222 |
| Deutsche Bank | 291,667 |
The underwriters have a 30-day option to purchase up to 1,458,333 additional shares from the company to cover over-allotments. The underwriting discount is $1.26 per share, totaling $12.250001 million without exercise of the option and $14.087501 million if exercised in full. Dealers may receive a discount of up to $0.756 per share from the IPO price.
The company estimates offering expenses, excluding underwriting discounts and commissions, of approximately $8.1 million. It will reimburse underwriters up to $80,000 for counsel fees and other expenses, and has paid William Blair $1.0 million in advisory fees. These payments are deemed underwriting compensation under FINRA Rule 5110. The company also agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act.
Lock-ups and potential share supply
The company, its officers and directors, and holders of substantially all of its share capital generally agreed not to dispose of or hedge shares or convertible securities for 180 days after the prospectus. The co-founders and affiliated entities are subject to 270-day lock-ups. Exceptions include certain gifts, estate, family and affiliate transfers; employee equity-award exercises and related tax sales; conversions; and other transfers with underwriter consent.
Additional exceptions allow the co-founders and vVARDIS Investment Holding AG to pledge shares and permit lenders to receive pledged shares if personal loans are enforced, as well as to refinance loans and make additional pledges. Company exceptions include equity-plan issuances and issuances for acquisitions or strategic transactions. Such transaction-related issuances are capped at 7.5% of Class A shares outstanding immediately after the offering, and recipients generally must accept the remaining 180-day lock-up. These exceptions could contribute to future share supply or dilution, although most shares received through conversions or awards remain locked up.
Pricing, trading and potential conflicts
No public market existed before the offering. The IPO price was negotiated with underwriter representatives, taking into account market conditions, the company’s performance and prospects, management, and comparable-company valuations. The shares were approved for listing on the NYSE under “VVVV.”
Underwriters may conduct short sales, open-market purchases, stabilizing transactions and penalty bids. These activities could prevent or delay a decline in the share price, making it higher than it otherwise might be, but are optional and may end at any time.
Underwriters and their affiliates have provided, and may continue to provide, banking, advisory, trading, investment-management, brokerage and other services to the company and related parties for customary fees. They may also trade or hold the company’s securities and related instruments, including long or short positions, for themselves or clients, and may publish independent research or recommendations. These activities may create potential conflicts of interest for investors.
Jurisdictional offering and resale restrictions
The offering is generally limited to jurisdictions and investor categories where local registration or prospectus exemptions apply. Restrictions include qualified- or professional-investor requirements and limits on offers to other investors in the EEA, UK, Canada, Hong Kong, Singapore, Australia, the DIFC and Switzerland; sales in Japan, Brazil and the UAE are also restricted. Australian purchasers are generally subject to a 12-month resale restriction. The prospectus is not registered or approved as a public offering document in several jurisdictions; in the DIFC, the shares may be illiquid or restricted from resale. The shares will not be listed or admitted to trading on a Swiss trading venue.
Expenses of the offering
Offering expenses
Estimated offering expenses, excluding underwriting discounts and commissions, total $8.142 million and will be paid entirely by the company. All amounts are estimates except the SEC registration, FINRA filing, and NYSE listing fees.
| Expense | Amount |
|---|---|
| SEC registration fee | $19,000 |
| FINRA filing fee | $33,000 |
| NYSE listing fee | $325,000 |
| Transfer agent fees and expenses | $30,000 |
| Printing | $185,000 |
| Legal fees and expenses | $4.600 million |
| Accounting fees and expenses | $1.600 million |
| Miscellaneous fees and expenses | $1.350 million |
| Total, excluding underwriting discounts and commissions | $8.142 million |
Legal matters
Legal matters
Homburger AG (Zurich) will advise the company on the validity of its Class A ordinary shares and certain Swiss-law matters. Davis Polk & Wardwell LLP (New York) will advise on certain U.S. federal and New York State law matters. Underwriters’ counsel are Lenz & Staehelin (Zurich) for Swiss-law matters and Covington & Burling LLP (New York) for U.S. federal and New York State law matters.
Experts
Deloitte AG, an independent registered public accounting firm, audited vVARDIS Holding AG’s financial statements as of December 31, 2025 and 2024, and for the years then ended. The prospectus includes those financial statements in reliance on Deloitte’s report and its accounting and auditing expertise. Deloitte AG’s registered business address is Pfingstweidstrasse 11, 8005 Zurich, Switzerland. This section identifies the auditor and contains no financial metrics, business developments, or specific risks.
Enforcement of judgments
Enforcement of Judgments
The company is organized and domiciled in Switzerland, where a number of its directors and executive officers reside and hold all or a substantial portion of their assets. Investors may therefore be unable to serve the company or those individuals in the United States, or to enforce U.S. court judgments against them, including judgments based on U.S. securities-law civil-liability claims.
Swiss counsel advises that enforcement in Switzerland of U.S. judgments—and original actions—based solely on U.S. federal or state securities laws is uncertain. Switzerland and the United States have no treaty providing for reciprocal recognition and enforcement of civil and commercial judgments. Under Switzerland’s Private International Law Act, Swiss courts may refuse to apply foreign law when its effect would conflict with Swiss public policy, and mandatory Swiss law may apply.
A U.S. judgment may be recognized in Switzerland only if the U.S. court had jurisdiction under Swiss law; the judgment is final and no longer appealable; it does not violate Swiss public policy; the proceedings and service of process satisfied due process; and no conflicting earlier proceeding or judgment exists.
Where you can find more information
Where to Find More Information
Upon completion of the offering, the company expects to become subject to the reporting requirements of the Securities Exchange Act, including filing annual reports on Form 20-F and reports on Form 6-K. As a foreign private issuer, it will be exempt from U.S. proxy-statement requirements. Its executives, directors, and principal shareholders will be exempt from Section 16 short-swing profit recovery, and principal shareholders will also be exempt from Section 16 reporting. The company will not be required to file periodic reports and financial statements as frequently or as promptly as U.S. domestic issuers.
The company’s website is provided for reference only. Website content is not incorporated by reference into the prospectus or registration statement.
Financial statements
FY2025 results and segment performance
vVARDIS develops, manufactures and sells dental care products. It has one operating and reportable segment; its Co-CEOs use consolidated net loss to assess performance and allocate resources. Revenue grew sharply, led by U.S. sales, but higher operating costs and financing expense widened losses.
| FY2025 line item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $30.209M | $12.157M |
| Cost of goods sold | $7.309M | $7.882M |
| Logistics | $0.483M | $0.386M |
| Total cost of revenue | $7.792M | $8.269M |
| Gross profit | $22.417M | $3.888M |
| R&D expense | $4.575M | $2.641M |
| SG&A expense | $59.925M | $32.213M |
| Operating loss | $(42.084)M | $(30.966)M |
| Interest expense | $11.753M | $3.942M |
| Net loss | $(56.447)M | $(34.737)M |
| Loss per share, basic and diluted | $(1.60) | $(1.11) |
| Weighted-average shares | 35.3453M | 31.3515M |
Revenue increased 148.5%. SG&A included $37.324M of people costs ($18.582M in FY2024), $12.015M of non-people costs ($6.698M), and $5.905M of marketing ($2.445M). Results also included a $1.647M loss on loans measured at fair value ($0.412M in FY2024) and a $1.628M loss on term-loan extinguishment (none in FY2024).
| Revenue by customer geography | FY2025 | FY2024 |
|---|---|---|
| U.S. | $28.737M | $10.938M |
| Italy | $0.354M | $0.288M |
| U.K. | $0.225M | $0.136M |
| Switzerland | $0.583M | $0.451M |
| Other countries | $0.310M | $0.344M |
Customer concentration is substantial: the largest customer accounted for 72% of revenue, up from 70%, and the second largest 13%, up from 8%. Two customers represented 68% of year-end receivables ($2.062M), compared with 63% ($1.282M) a year earlier.
Cash flow and balance sheet
| Cash flow | FY2025 | FY2024 |
|---|---|---|
| Operating cash flow | $(16.333)M | $(23.797)M |
| Investing cash flow | $(2.805)M | $(0.325)M |
| Property and equipment purchases | $(0.760)M | $(0.047)M |
| Intangible asset purchases | $(2.045)M | $(0.278)M |
| Financing cash flow | $31.978M | — |
| Cash, cash equivalents and restricted cash, year-end | $17.681M | $2.405M |
Operating cash use improved partly because deferred revenue increased by $15.000M. Financing included $66.453M of non-current loan proceeds, $15.715M of warrant proceeds and $48.000M of long-term debt repayments. Cash and cash equivalents on the balance sheet were $17.470M, plus $0.211M restricted cash. Interest paid rose to $6.452M from $0.492M.
| Balance-sheet item | Dec. 31, 2025 | Dec. 31, 2024 |
|---|---|---|
| Total assets | $83.228M | $55.907M |
| Total liabilities | $143.545M | — |
| Total shareholders’ equity (deficit) | $(104.789)M | $(75.973)M |
| Goodwill | $13.387M | $11.751M |
| Intangible assets, net, excluding goodwill | $31.823M | $29.748M |
| Loans, net of discounts and issuance costs | $104.600M | $72.943M |
| Cash and cash equivalents | $17.470M | $2.343M |
Goodwill relates to the 2020 Credentis AG acquisition; its FY2025 increase reflected $1.636M of favorable currency translation, with no impairment in either year. Intangible assets increased mainly due to software additions and currency translation. Owners’ equity was a deficit of $103.656M; after goodwill and intangible assets, owner-attributable tangible equity was approximately $(148.866)M. Redeemable Series A preferred shares of $44.472M are mezzanine equity.
Debt, liquidity and other exposures
The company repaid its 8% 2029 PIK loan in June 2025; principal and accrued interest totaled $48.584M. The transaction involved shareholders acquiring the obligation and offsetting reciprocal company-provided funds. New 2030 term-loan commitments began at $35.000M and increased by $50.000M to $85.000M. The first tranche carries interest of 7.5% plus the greater of one-month SOFR or 3.5%; the second carries 12.5% plus that benchmark. Both mature in February 2030. Year-end non-current debt maturities, excluding discounts, costs and fair-value adjustments, were $119.792M: $1.322M in 2026, $29.991M in 2027 and $88.479M in 2030. Debt issuance discounts and costs rose to $19.059M from $0.200M.
The $15.000M 2027 convertible loan’s rate increased from 6% to 7% in February 2025, with interest capitalized. Its year-end fair-value liability was $17.236M, versus $15.412M; FY2025 remeasurement was $1.824M. Related 2026 convertible loans totaled $1.329M at year-end. The 2026 term-loan maturities were extended to June 2027 in January 2026. Minimum-liquidity and other covenants apply; the company reported compliance or applicable waivers/consents at year-end.
Deferred revenue was $15.000M, comprising $7.500M expected within 12 months and $7.500M thereafter, from distributor prepayments for products expected to be sold in 2026–2027. Net receivables were $3.042M ($2.037M in 2024). Net inventory was $8.616M ($8.334M); the excess/obsolete inventory provision fell to $0.279M from $3.916M, mainly after reserved inventory was scrapped or disposed of. Supplier advances increased to $2.065M current, plus $1.002M non-current for inventory expected in 2027–2028, to secure production capacity, continuity and sometimes favorable pricing.
Equity, tax and subsequent events
Ordinary shares outstanding increased from 31.731320M at the start of FY2025 to 31.822153M at year-end; 6.856795M Series A preferred shares remained outstanding. Series A has a 2.0x dividend and liquidation preference and is contingently redeemable. Potentially dilutive securities excluded from diluted EPS as anti-dilutive totaled 8.743860M: 6.856795M preferred shares, 0.892777M options and 0.994288M share-based awards.
Share-based compensation increased to $13.884M from $5.890M. Year-end non-vested RSUs were 0.994288M, with $12.695M unrecognized compensation cost; 0.892777M options were outstanding, with $10.391M unrecognized cost and $13.130M aggregate intrinsic value. Both unrecognized amounts were expected to be recognized over three years. A Swiss defined-benefit pension plan had a $1.126M funded deficit, versus $1.229M in 2024.
The FY2025 effective tax rate was 0.65%, versus 1.13%, principally reflecting a $7.916M valuation-allowance effect. Gross deferred tax assets were $33.822M, including $32.534M from net operating loss carryforwards; a $31.985M valuation allowance left net deferred tax assets of $1.837M. NOLs totaled $220.770M, including $111.706M of Swiss NOLs expiring in two to five years.
In April 2026, an investor contributed $32.0M for Series B preferred shares. The $15.0M 2027 convertible-loan principal and $1.837M accrued interest converted into Series B shares; 2026 convertible loans were converted or repaid. A five-for-three forward share split approved in August 2026 and effected in September was applied retrospectively to share and per-share figures.
The company has incurred recurring losses and had a $228.515M accumulated deficit at year-end. Management concluded substantial doubt about going concern did not exist, citing cash, expected operating cash flows and available financing, though continued losses and cash use make external financing important. Deloitte issued an unqualified opinion on the financial statements but did not audit internal control effectiveness.
Financial statements
vVARDIS Holding AG — H1 2026 financial statements
Unaudited; USD unless noted. H1 figures are for the six months ended June 30.
Results
The Group has one operating and reportable segment, developing, manufacturing, selling, and distributing dental-care products, primarily through distributors. Revenue more than tripled, while the operating and net losses narrowed. Higher R&D and interest costs remained significant drags.
| H1 result | H1 2026 | H1 2025 |
|---|---|---|
| Revenue | $28.558M | $9.088M |
| Cost of goods sold | $3.885M | $4.417M |
| Operating loss | $(17.550)M | $(24.081)M |
| Net loss | $(27.807)M | $(32.057)M |
| Interest expense | $9.015M | $4.061M |
| Basic and diluted loss per share | $0.70 | $0.93 |
| Weighted-average ordinary shares | 39.948M | 34.620M |
The reported H1 revenue increase was 214.2%. R&D expense rose to $7.159M from $2.002M, and SG&A rose to $35.064M from $26.750M. Other notable items included a $1.580M term-loan extinguishment loss and a $1.613M gain on loan conversion. The company reported a $0.350M income-tax benefit, compared with $0.026M of tax expense; valuation allowances limit recognition of deferred tax benefits in certain jurisdictions.
Revenue concentration and deferred revenue
The U.S. generated $27.138M of H1 revenue, compared with $7.972M; other reported markets were Italy ($0.533M vs. $0.261M), the U.K. ($0.442M vs. none), Switzerland ($0.317M vs. $0.635M), and other regions ($0.128M vs. $0.220M). The largest customer accounted for 90% of H1 sales, up from 62%; the second largest accounted for 5%, down from 13%, representing significant customer concentration.
A distributor advance resulted in $15.000M of deferred revenue at both June 30, 2026 and December 31, 2025. It was all current at June 30; at year-end, $7.500M was current and $7.500M non-current. Recognition was expected to begin in Q3 2026, and none of the year-end balance was recognized during H1. Revenue is recognized when product control transfers; distributor rebates reduce revenue and rely on sell-through estimates.
Cash flow and balance sheet
| Cash flow | H1 2026 | H1 2025 |
|---|---|---|
| Net cash used in operating activities | $(16.317)M | $(22.755)M |
| Capital expenditures — property and equipment | $0 | $0.078M |
| Capital expenditures — intangible assets | $0 | $0.169M |
Financing activities provided $29.924M, including $31.656M of Series B preferred-share proceeds. Cash, cash equivalents, and restricted cash ended H1 at $29.181M, compared with $17.681M at the start of the period; this included $28.974M of balance-sheet cash and cash equivalents and $0.207M of restricted cash. The company has incurred recurring losses since inception, with a $256.322M accumulated deficit, although management concluded substantial doubt about going concern did not exist, citing cash, expected operating cash flows, and available financing arrangements.
| Balance-sheet item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $104.803M | $83.228M |
| Total liabilities | $164.408M | $143.545M |
| Total shareholders’ equity (deficit), including non-controlling interests | $(118.502)M | $(104.789)M |
| Goodwill | $13.123M | $13.387M |
| Intangible assets other than goodwill, net | $29.076M | $31.823M |
| Cash and cash equivalents | $28.974M | $17.470M |
June 30 net finite-lived intangibles comprised trademarks of $3.597M, patents of $23.666M, and software of $1.813M. Goodwill declined $0.264M solely from foreign-currency translation; the company reported no impairment or triggering event since its December 2025 annual test. Net receivables were $7.220M, up from $3.042M, with a $0.201M allowance; net inventory was $10.711M, up from $8.616M. The increase in accrued operating expenses to $8.900M from $4.482M included higher accrued consulting and other services, rebates, and inventory purchases.
Debt, covenants, and preferred financing
Loans’ carrying value was $84.207M at June 30, versus $104.600M at year-end; current maturities were $17.204M versus $1.390M, and non-current loans were $67.003M versus $103.210M. Unamortized discounts and issuance costs were $25.607M versus $19.059M. The two 2026 term-loan tranches, bearing 8%, were extended to June 2027 and classified current. The 2030 term loan comprises a $35M Tranche I at 7.5% plus the greater of one-month SOFR or 3.5%, and a $50M Tranche II at 12.5% plus the same floor; both mature in February 2030. Aggregate non-current debt maturities in 2030 were $92.610M of principal, excluding discounts, issuance costs, and fair-value adjustments. Effective rates at June 30 were 24.6% and 31.8% for Tranches I and II.
The company was not compliant with certain 2030 loan covenants at June 30 following liquidation of two subsidiaries. A September 2026 lender waiver, covering $92.610M of outstanding principal, prevents acceleration or demand for repayment through March 14, 2027, allowing the debt to remain non-current; compliance remains a material financing risk. The company also missed a required $5.0M ordinary-share proceeds deadline, incurring a $898K fee that was paid in kind and added to principal. The 2027 convertible loan, including $15.0M principal and accrued interest, converted into 598,570 Series B preferred shares in April; no loan liability remained at June 30.
Series A and B preferred shares had a combined carrying value of $58.897M and aggregate liquidation preference of 178,475 (table amounts in thousands, except per-share amounts). Series B ranks ahead of Series A and ordinary shares and carries a 3.0x minimum-investment-return preference, or the greater as-converted value; Series A has a 2.0x preference and ranks behind Series B. Series B exit and repurchase rights could create future financing or dilution demands. Both classes are mezzanine equity; neither was considered redeemable or likely to become redeemable at June 30. Series B conversion, redemption, and exit features generated a separate Level 3 derivative liability of $31.409M, measured using a Monte Carlo model and assumptions including the likelihood of an IPO exit; H1 remeasurement loss was $0.008M.
Equity, dilution, and other matters
Ordinary shares outstanding increased from 31.822M at December 31, 2025 to 34.187M at June 30, 2026. H1 financing included $31.656M of Series B proceeds and conversion of $16.837M of 2027 convertible loans into preferred shares; management convertible loans also converted into ordinary shares. Potential securities excluded from diluted EPS as anti-dilutive totaled 9,046,118 shares in H1 2026, versus 9,208,133 in H1 2025, including preferred shares, options, and share-based awards. Share-based compensation expense was $4.007M versus $6.358M. A five-for-three forward split approved August 24 and effected September 15, 2026 was reflected retrospectively in share and per-share data. The company capitalized $2.148M of planned IPO costs, to be offset against IPO proceeds if completed or expensed if terminated.